6.
Dave K, Ali A, Magalhaes M
. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Sci Rep. 2020; 10(1):9705.
PMC: 7297711.
DOI: 10.1038/s41598-020-66257-6.
View
7.
Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F
. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology. 2015; 4(4):e1001224.
PMC: 4485754.
DOI: 10.1080/2162402X.2014.1001224.
View
8.
de Souza Malaspina T, Gasparoto T, Costa M, de Melo Jr E, Ikoma M, Damante J
. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother. 2011; 60(7):965-74.
PMC: 11028705.
DOI: 10.1007/s00262-011-1007-5.
View
9.
Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D
. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol. 2016; 139(1):335-346.e3.
DOI: 10.1016/j.jaci.2016.04.025.
View
10.
Woo S
. Oral Epithelial Dysplasia and Premalignancy. Head Neck Pathol. 2019; 13(3):423-439.
PMC: 6684678.
DOI: 10.1007/s12105-019-01020-6.
View
11.
Palefsky J, Silverman Jr S, Daniels T, Greenspan J
. Association between proliferative verrucous leukoplakia and infection with human papillomavirus type 16. J Oral Pathol Med. 1995; 24(5):193-7.
DOI: 10.1111/j.1600-0714.1995.tb01165.x.
View
12.
Carson D, Lois A
. Cancer progression and p53. Lancet. 1995; 346(8981):1009-11.
DOI: 10.1016/s0140-6736(95)91693-8.
View
13.
Gouvea A, Vargas P, Coletta R, Jorge J, Lopes M
. Clinicopathological features and immunohistochemical expression of p53, Ki-67, Mcm-2 and Mcm-5 in proliferative verrucous leukoplakia. J Oral Pathol Med. 2010; 39(6):447-52.
DOI: 10.1111/j.1600-0714.2010.00889.x.
View
14.
Salome B, Sfakianos J, Ranti D, Daza J, Bieber C, Charap A
. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell. 2022; 40(9):1027-1043.e9.
PMC: 9479122.
DOI: 10.1016/j.ccell.2022.08.005.
View
15.
Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T
. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018; 175(7):1731-1743.e13.
PMC: 6292840.
DOI: 10.1016/j.cell.2018.10.014.
View
16.
Rebaudi F, De Rosa A, Greppi M, Pistilli R, Pucci R, Govoni F
. A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans. Front Immunol. 2023; 14:1216107.
PMC: 10358763.
DOI: 10.3389/fimmu.2023.1216107.
View
17.
Campisi G, Giovannelli L, Ammatuna P, Capra G, Colella G, Di Liberto C
. Proliferative verrucous vs conventional leukoplakia: no significantly increased risk of HPV infection. Oral Oncol. 2004; 40(8):835-40.
DOI: 10.1016/j.oraloncology.2004.02.007.
View
18.
Warnakulasuriya S, Kujan O, Aguirre-Urizar J, Bagan J, Gonzalez-Moles M, Kerr A
. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2020; 27(8):1862-1880.
DOI: 10.1111/odi.13704.
View
19.
Mello F, Miguel A, Dutra K, Porporatti A, Warnakulasuriya S, Guerra E
. Prevalence of oral potentially malignant disorders: A systematic review and meta-analysis. J Oral Pathol Med. 2018; 47(7):633-640.
DOI: 10.1111/jop.12726.
View
20.
Jyothi Meka N, Ugrappa S, Velpula N, Kumar S, Maloth K, Kodangal S
. Quantitative Immunoexpression of EGFR in Oral Potentially Malignant Disorders: Oral Leukoplakia and Oral Submucous Fibrosis. J Dent Res Dent Clin Dent Prospects. 2015; 9(3):166-74.
PMC: 4682013.
DOI: 10.15171/joddd.2015.031.
View